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Tuberculosis (TB) is a serious infectious disease that affects more than new 10 million patients 18 
each year. Many of these cases are resistant to first‐line drugs so second‐line ones, like 19 
fluoroquinolones, need to be incorporated into the therapeutic. Ofloxacin (OF) is a 20 
fluoroquinolone which demonstrates high antibiotic activity against the bacteria that causes TB 21 
(M. tuberculosis). In this work, ionic complexes, composed by hyaluronic acid (HA) and OF, with 22 
different neutralization degrees, were prepared and processed by spray drying (SD) to obtain 23 
powders for inhalatory administration. Combining a formulation with high neutralization degree, 24 
high SD atomization air flowrate and the use of a high-performance collection cyclone, very good 25 
process yields were obtained. Carrier-free formulations with a loading of 0.39-0.46 gOF/gpowder 26 
showed excellent emitted, fine particle, and respirable fractions for capsule loadings of 25 and 100 27 
mg. The ionic complexes demonstrated higher mucoadhesion than pure OF and HA. The best 28 
formulation did not affect CALU-3 cell viability up to a dose 6.5 times higher than the MIC90 29 
reported to treat multi-drug resistant TB.  30 
Keywords:  31 
Fluoroquinolones, hyaluronic acid, drug-excipient interaction, multi-drug resistant tuberculosis, 32 
inhalation, cell viability, mucoadhesive, spray drying 33 
  34 
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1. Introduction 35 
The inhalatory route is considered a promising non-invasive alternative for drug administration to 36 
treat systemic or pulmonary illnesses. For pulmonary diseases, this route delivers the drug directly 37 
to the action site minimizing the systemic distribution and side effects. Then, a high concentration 38 
of the active pharmaceutical ingredient and rapid onset can be achieved. Consequently, lower 39 
doses are often required. Inhalatory route has been used for obstructive illnesses, like chronic 40 
obstructive pulmonary diseases (COPD) and asthma, but is also relevant for treatment of 41 
infections, like tuberculosis (TB) and those associated with cystic fibrosis1,2,3,4. 42 
To treat respiratory infections, antibiotics are usually administered by the oral route. Orally 43 
administered drugs have problems reaching the lungs by systemic distribution. So the delivery of 44 
antimicrobials by the inhalatory route has been proposed3. However, the performance of inhaled 45 
aerosols depends on particle properties like size, morphology and density5. For this reason, a 46 
rational design of the inhalatory system is required for a successful pharmacotherapy.  47 
Treatments by pulmonary route could be also improved by, for example, increasing drug residence 48 
time in the lungs or modifying the active ingredient dissolution rate6. In this sense, by combining 49 
ionizable drugs with opposite charged polymers (polyelectrolytes) new chemical entities can be 50 
obtained with specific and differentiated properties respect to the precursor active ingredient7. 51 
Different antibiotics have been formulated by using this strategy to be administered by the 52 
inhalatory route. Among others, nanoaggregates of nanoparticles containing vancomycin were 53 
obtained by ionic interaction with polyacrylic acid where the polyelectrolyte stabilized the 54 
nanoaggregates avoiding agglomerations8. Cheow and Hadinoto9 and Kho and Hadinoto10 55 
produced systems composed by fluoroquinolones and dextran, where the polyelectrolyte allowed 56 
obtaining amorphous co-processed formulations. For TB treatment, Zahoor et al. produced 57 
nanoparticles by combining sodium alginate with rifampicin, isoniazid and pyrazinamide. The 58 
polyelectrolyte allowed prolonging the drug residence time and thus reducing the administration 59 
frequency11. Swai et al. produced systems combining poly-lactid-co-glycolic acid or 60 
chitosan/alginate with isoniazid12 and Manca et al. obtained microparticles of carrageenan and 61 
chitosan carrying rifampicin liposomes13. In both reports, the ionic interaction increased the drug 62 
residence time.  63 
As previously stated, some inhalatory formulations were developed for TB. It was estimated that 64 
just in 2015 there were 10 million new cases of tuberculosis all over the world, killing almost 2 65 
million persons. What is more, 5.5 % of the 2015 new cases were resistant to first‐line drugs 66 
(mainly rifampicin, isoniazid and pyrazinamide). When drug resistance is detected, second-line 67 
drugs are incorporated to the therapeutic and the treatment duration is increased14,15. 68 
Fluoroquinolones are considered to be an important pharmacological group for alternative TB 69 
treatments16. In this sense, ofloxacin (OF) possesses high antibiotic activity against M. tuberculosis, 70 
including those strains resistant to rifampicin.  71 
Then, new materials carrying OF would be of great interest for the pharmacotherapy of resistant 72 
TB. In this sense Park et al.3, produced chitosan crosslinked with glutaraldehyde microparticles 73 
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carrying OF by water-in-oil emulsification method. The aqueous phase was composed of ofloxacin, 74 
chitosan and acetic acid while the oil phase was prepared using dichloromethane, paraffin, 75 
surfactants and emulsifiers. The authors focused on the uptake of the microparticles by alveolar 76 
macrophages in rat alveolar macrophages cell line and demonstrated that microparticles were 77 
uptaken in a higher proportion than pure OF3. Hwang et al. developed microspheres containing OF 78 
and the sodium salt of hyaluronic acid (HANa) by spray drying an ethanolic solution containing 79 
these compounds17. They administered pure OF, spray-dried OF and spray-dried OF-HANa 80 
formulations to rats by oral, intratracheal and intravenous routes. For the intratracheal 81 
administration, the authors demonstrated that the OF lung concentration was higher and the OF 82 
plasmatic concentration was lower respect to the contents found for the oral and intravenous 83 
routes17. The OF lung/OF plasma concentrations ratio for the inhalatory administration of the OF-84 
HANa system was about two times higher than the ratio found when pure OF was intratracheally 85 
delivered. These authors also found that the OF-HANa microparticles, as reported for the OF-86 
chitosan formulation, were uptaken in a higher proportion than pure OF by alveolar macrophages. 87 
Park et al. and Hwang et al., evaluated the aerosolization properties of the OF-chitosan and OF-88 
HANa powders, respectively, in a twin-impinger when delivered from a dry powder inhaler (DPI) 89 
system. The fine particle fraction for sizes lower than 6.4 µm was 43 % and 45 % for OF-HANa and 90 
OF-chitosan systems, respectively3,17. 91 
The previously developed systems carrying OF exhibited attractive biopharmaceutical 92 
performance and in vivo macrophages uptake in lab animals3,17. However, both contributions used 93 
organic solvents for the OF dissolution previous to powder production. In this work, the 94 
development of a polyelectrolyte-drug ionic complex constituted by OF-hyaluronic acid (HA) is 95 
used as strategy to dissolve OF without using organic solvents, being in this sense an innovative 96 
way to produce OF microparticles for inhalatory administration. Then, the objective of this work is 97 
the production of OF-HA microparticles by a simple method with optimized aerosolization 98 
properties, as a carrier-free DPI. To this aim, a complete physicochemical characterization of the 99 
particulate systems was performed to establish relationships between process parameters and 100 
product quality. The OF-HA microparticles were obtained by processing aqueous solutions by 101 
spray drying and varying the feed formulation (i.e., OF/HA ratios) and operating conditions. The 102 
process performance (SD yield and air outlet temperature), product properties (OF loading, 103 
crystallinity, morphology and particle size), the OF-HA ionic interaction (assessed by Fourier 104 
transform infrared spectroscopy and powder X-ray diffraction), in vitro aerosolization performance 105 
(using a multistage cascade impactor), mucoadhesion and CALU-3 cell viability were evaluated to 106 
study the proposed formulations.  107 
2. Materials and methods 108 
 109 
2.1. Materials 110 
Sodium hyaluronan (NaHA, MW: 1655 kDa, proanalysis grade, Parafarm, Saporiti, Buenos Aires, 111 
Argentina), ofloxacin (pharmaceutical grade, Parafarm, Saporiti, Buenos Aires, Argentina), sulfonic 112 
acid resin Amberlite® IR 120 in hydrogen form (proanalysis grade, Sigma–Aldrich, Saint Louis, 113 
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United States), sodium hydroxide 0.01 M (proanalysis grade, Anedra, Argentina), hydrochloric acid 114 
10 M (proanalysis grade, Anedra, Buenos Aires, Argentina), potassium bromide (spectroscopic 115 
grade, Merck, Darmstadt, Germany), size 3 gelatine capsules (pharmaceutical grade, Parafarm, 116 
Saporiti, Buenos Aires, Argentina), lactose monohydrate (pharmaceutical grade, Parafarm, 117 
Saporiti, Buenos Aires, Argentina) with particle sizes between 70 and 140 mesh sieves (ASTM), 118 
glycerin (pharmaceutical grade, Anedra, Buenos Aires, Argentina), potassium phosphate 119 
monobasic (analytical grade, Anedra, Buenos Aires, Argentina), sodium hydroxide (analytical 120 
grade, Anedra, Buenos Aires, Argentina) and distilled water were used. 121 
For the assays in cell cultures, CALU-3 cells (ATCC® Cat# HTB55, bronchial human epithelial airway 122 
cells) were used. Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), penicilin-123 
streptomycin, L-Glutamine, non-essential amino acids and trypsine were all from Life 124 
Technologies, GIBCO BRL, Rockville, USA. CellTiter 96® AQueous Non-Radioactive Cell Proliferation 125 
Assay was purchased from Promega, Madison, USA.  126 
 127 
2.2. Methods 128 
2.2.1.  Preparation of the HA solution 129 
To obtain the HA solution, a 0.5 % w/v aqueous solution of NaHA was prepared and passed 130 
through a glass column packed with sulfonic acid resin (previously activated with HCl ≈ 10 M). The 131 
HA solution was collected when the pH of the eluted was 3. 132 
2.2.2.  Determination of number of acid equivalents  133 
The number of acid equivalents in the HA solution was determined by potentiometric titration 134 
using NaOH (0.01 M). The evaluated solution had 2.11 x 10-3 acid equivalents of HA per gram.  135 
2.2.3.  Preparation of solutions to be spray dried  136 
Table 1 shows the theoretical composition of solutions prepared to be spray dried. Two aliquots 137 
(200 mL each) of the HA solution (obtained as described in Section 2.2.1) were mixed with 138 
different amounts of the drug in order to neutralize about 75 and 100 % of the HA available acidic 139 
groups. For this, an appropriate mass of the drug, which represents the available acid groups to 140 
neutralize was weighted and incorporated under constant magnetic stirring. The theoretical total 141 
solid content in these solutions varied from 0.42 to 0.56 % (w/w). The samples were named 142 
according to their theoretical composition as (HA-OF)x, where the subscript x refers to the 143 
neutralization degree of HA acidic groups (i.e., x= 75 or 100). The pH of the resulted solutions was 144 
measured using a pH meter Orion 410A, Cole Parmer, Vermon Hills, United States.  145 
2.2.4.  Spray drying (SD) process 146 
The solutions, prepared as described in Section 2.2.3, were fed in a negative pressure laboratory 147 
scale SD equipment (Mini Spray Dryer B-290, BÜCHI, Flawil, Switzerland) with a two-fluid nozzle 148 
(cap-orifice diameter: 0.5 mm). Based on exploratory experiments, two sets of process parameters 149 
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were selected, which are summarized in Table 2. For comparison purposes, an aqueous solution of 150 
pure OF and pure HA were also atomized. The process yield (PY) was calculated as the ratio of the 151 
weight of product collected after the spray drying process respect to the initial total solid content. 152 
2.2.5.  Powder characterization 153 
• Drug loading: SD powders were dissolved in distilled water and ofloxacin concentration 154 
was determined by UV-spectrophotometry (T60, PG instruments, Lutterworth, UK) at 155 
289 nm. The results were reported as gram of drug per gram of powder.  156 
• Fourier Transformed Infrared Spectroscopy (FTIR). Samples (SD materials and raw OF) 157 
were studied in 1-1.5 % w/w potassium bromide (KBr) compacts using a FT-IR instrument 158 
(Nexus FT, Termonicolet, Maryland, United States). Before analysis, samples and KBr were 159 
dried at 105 °C.  160 
• Powder X-ray Diffraction (PXRD). An X-ray powder diffractometer (Philips PW 1710, Philips 161 
Industrial & Electro-acoustic Systems Division, Almelo, Netherlands) was used to assess 162 
the crystallinity of pure drug and SD powders. Sample diffractograms were obtained under 163 
previously reported conditions.18,19 164 
• Particle morphology. The morphological characteristics of the pure and co-processed 165 
materials were evaluated through Scanning Electron Microscopy (SEM) using an EVO 40-166 
XVP, LEO scanning electron microscope (Oberchoken, Germany).18,19  167 
• Particle size. Size distributions were measured by laser diffraction using the dry powder 168 
method (LA 950 V2, Horiba, Kyoto, Japan). The spray-dried powders were dispersed in 169 
lactose (with a known particle size distribution) in a proportion lactose:sample 4:1 to 170 
improve the sample flow from the feed hopper to the measuring cell. The volume average 171 
diameter of lactose differs substantially from the average size of the powder obtained by 172 
spray drying. As a consequence, bimodal distributions, with two modes perfectly 173 
distinguishable were obtained allowing an accurate granulometry measurement. Size is 174 
reported as mean volumetric diameter (D43) and distribution width is informed as span.
18  175 
• Drug distribution. The presence of drug in the microparticles was studied by fluorescence 176 
confocal microscopy (TCS SP2, LEICA, Wetzlar, Germany) for (HA-OF)75 sample. A small 177 
amount of material was placed in a capsule and excited with an argon laser at 488 nm. An 178 
immersion objective of 63 X was used. 179 
 180 
2.2.6. Aerodynamic characterization 181 
The in vitro aerosolization performance was studied on a Next Generation Impactor (NGI, Copley 182 
Scientific, Nottingham, UK20) equipped with an induction port (IP) and a pre-separator (PS), filled 183 
with 15 mL of water, as previously described21. Size 3 gelatin capsules were filled with 25±0.50 mg 184 
of SD products and the powder was dispersed using an RS01 high resistance inhaler (Plastiape, 185 
Milano, Italy) into the NGI. The air flowrate was fixed at 58.8 L/min in order to reach a pressure 186 
drop of 4 kPa as indicated by the USP22 and 4 L of air passed through the equipment. Drug content 187 
in each stage was assessed using a UV-spectrophotometer at 289 nm. 188 
7 
 
The Emitted Fraction (EF), Fine Particle Fraction (FPF), Respirable Fraction (RF), Mass Median 189 
Aerodynamic Diameter (MMAD) and Geometric Standard Deviation (GSD) were determined as 190 
follows23,24,25:  191 
• EF: represents the drug percentage of total drug loaded in the capsule that is effectively 192 
released from the capsule and the inhaler; 193 
• FPF: is the percentage of cumulative drug mass with aerodynamic diameters lower than a 194 
given size (the cumulative size distribution is built considering the drug mass collected in 195 
1st to 7th NGI stages and the multiple orifice collector (MOC)) relative to the total drug 196 
mass recovered from the mouth piece adaptor (MA), PS, IP, 1st to 7th NGI stages and MOC;  197 
• RF: accounts for the cumulative percentage of drug mass with aerodynamic diameters 198 
lower than a given size respects to the total drug mass recovered from the capsule, 199 
inhaler, MA, PS, IP, 1st to 7th NGI stages and MOC.  200 
• The MMAD was calculated from the drug mass cumulative distribution and is defined as 201 
the diameter at which 50 % of the drug is collected in larger particles and the remaining 202 
50 % is collected within smaller particles.  203 
• The GSD, that represents the spread of an aerodynamic particle size distribution, was 204 
calculated as (D84/D16)
1/2, where D84 and D16 represent the diameters at which 84 % and 205 
16 % of the drug mass recovered from the 1st to 7th NGI stages and MOC, respectively. 206 
With the aim to estimate the dose of the best HA-OF product required to treat the multi-drug 207 
resistant TB, the formulation was assayed at a higher capsule loading. For this, the size 3 gelatin 208 
capsule was filled with 100 mg of powder (without applying any force or compressing the 209 
powder) and the study was carried out under the same conditions than previously described. EF, 210 
FPFs, RFs, MMAD and GSD parameters were calculated. 211 
 212 
2.2.7. Cell culture and viability assay 213 
In order to preliminary assess the cytotoxic effect of the microparticles, CALU-3 cell line (derived 214 
from human bronchial submucosal glands) was used. CALU-3 cells were cultured in DMEM 215 
medium supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-216 
Glutamine and non-essential amino acids at 37 °C under 5 % CO2 in humidified incubator, as 217 
previously described26. 218 
For viability assays, CALU-3 cells were seeded in 96-well plates (80,000 cells/well in 100 μL 219 
complete DMEM medium) during 24 hours at 37 °C under 5 % CO2 in humidified incubator. 220 
(AH-OF)x stock solution (20 mM) was prepared in distilled water. Cells were incubated with serum-221 
free DMEM (considered controls) or with different concentrations of (AH-OF)100 to reach a final 222 
concentration of 0.015, 0.03, 0.06, 0.1, 0.3 and 0.6 mM of ofloxacin in serum-free DMEM during 223 
24 more hours. Cell viability was evaluated by using the CellTiter 96® AQueous Non-Radioactive 224 
Cell Proliferation Assay, according to manufacturer´s instructions. Briefly, after the 24 hours 225 
treatment, cells were washed with PBS (pH 7.4) and treated with staining solution containing the 226 
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MTS tetrazolium salt. MTS is reduced by mitochondrial oxidases into a formazan product that is 227 
soluble in tissue culture. This bioreduction is associated with metabolic activity. Absorbance was 228 
recorded at 490 nm using a microplate reader (Benchmark, Bio-Rad, Hercules, USA) and is directly 229 
proportional to the number of living cells27. Results are expressed in arbitrary units as % of the 230 
control condition. 231 
2.2.8. Mucoadhesion assay: Tensile Strength  232 
The mucoadhesion properties of the (AH-OF)x sample were studied using a TA Plus texture 233 
analyzer (Lloyd Instruments, Godalming, UK) equipped with a 5-kgf load cell. The technique was 234 
adapted from Gallo et al6. Briefly, 0.1 mL of a mucin solution (3 % in PBS pH 7.4 kept at 37±0.5 °C) 235 
was placed over a filter paper (2 cm diameter). The filter paper was attached to a stationary 236 
surface and the mucin solution was allowed to stand for 15 minutes. A mobile metallic probe was 237 
placed above the stationary surface. A monolayer of microparticles carrying OF were attached to 238 
the mobile probe. The mobile probe was lowered, without applying any force, until it soaked in 239 
the mucin solution for 3 min. Finally, the probe was raised at withdrawal speed of 0.1 mm/s. The 240 
maximum detachment force (MDF) and the total work (TW) were measured using the computer 241 
software (Nexygen Plus). The reported results are expressed as the average of six measurements. 242 
 243 
2.2.9. Statistical analysis 244 
The significant differences between the mean volumetric diameter, aerodynamic behavior, cell 245 
viability and mucoadhesion test were determined by means of one-way ANOVA followed by least 246 
significant difference (LSD) test to compare means. Statistical significance was established through 247 
the p-value: values lower than 0.05 were considered statistically significant 248 
 249 
3. Results 250 
3.1. Spray drying: feed composition, feed properties and operating conditions  251 
HA is a natural polysaccharide with anionic groups in its structure (pKa 328, Figure 1.a). It has N-252 
acetyl d-glucosamine and β-glucuronic acid as repetitive units. Due to the non-immunogenicity 253 
and biocompatibility properties, it has been used for different pharmacological and clinical uses. 254 
HA has been proposed for the inhalatory route because increases the bioadhesivity of different 255 
therapeutic agents.29 It is approved in some European countries to reduce bronchial reactivity 256 
associated to allergens or pollutants inhalation or caused by physical effort. A combination of HA 257 
with hypertonic saline solution is also approved for reducing mucus viscosity in cystic fibrosis 258 
patients.30 Specifically for TB treatments by the inhalatory route, HA is biologically recognized by 259 
receptor CD44 in alveolar macrophages. That recognition improves internalization of anti-TB 260 
formulations containing both drugs and HA. Besides receptor-mediated phagocytosis, HA can 261 
polarize macrophages (leading to an inflammatory response and macrophages activation) and 262 
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then improve TB treatments31. In fact, HA has been employed to develop inhalatory delivery 263 
systems in order to modify dissolution rate and target macrophages for different drugs.31,32,33,34  264 
As with others anionic polyelectrolytes, HA acidic groups have the capability to interact with 265 
cationic compounds.18,35 OF is a zwitterionic fluoroquinolonic drug containing both anionic and 266 
cationic groups (pKas 5.9 and 8.336, Figure 1.b). This drug is slightly soluble in water37. The ionic 267 
interaction between HA and OF in an aqueous medium would lead to the formation of ionic pairs.  268 
All feed solutions prepared for being processes by SD did not evidence precipitation or phase 269 
separation, even when the (HA-OF)100 feed was formulated. For this solution, the OF concentration 270 
was around 0.0028 g/mL which is 7.7 % higher than the OF water solubility at 25 °C and pH=738. 271 
Considering that for a given temperature the OF water solubility is a strong function of the pH37, 272 
the absence of precipitation can be explained by two combined effects: the acidic resulting pH 273 
(around 5, see Table 1) and the improvement of the OF water compatibility due to the ionic 274 
interaction with hyaluronic acid39. In any case, the use of HA allowed obtaining aqueous solutions 275 
for spray drying without the need for organic solvents3,17. 276 
Table 1 shows the pH of different feed solutions. The HA pure solution showed the lowest pH 277 
value within the assayed solutions. As the neutralization of the free HA acidic groups of the 278 
polyelectrolyte was increased (from x=75 to x=100), the pH increased from 4 to around 5.  279 
The feed solutions were processed in a spray dryer using the process parameters detailed in Table 280 
2. The resulting SD outlet air temperature (Tout) and the process yield (PY) are shown in Table 3. 281 
When the set I of the operating conditions was used, the Tout was lower than 80 °C for all the 282 
formulations. This value is well below the degradation temperatures of OF and HA. In fact, OF 283 
thermal degradation starts over 250 °C40 while hyaluronic acid decomposition occurs above 284 
300 °C41. Considering this, thermal degradation during the spray-drying process is not expected. 285 
For set I, PYs of co-processed products were around 50 %, satisfactory level for a lab scale 286 
equipment42.  287 
The set II of process parameters increased the atomization air flowrate (aiming to reduce the 288 
particle size) respect to the value of set I, and replaced the standard cyclone by a high 289 
performance one (from BÜCHI) to improve the collection efficiency. According to Table 3 and for 290 
samples with a neutralization degree of 75 and 100 %, the PYs increased more than 35 % when 291 
process conditions changed from set I to set II. Simultaneously, the outlet temperature was 292 
reduced. So, set II improved the SD global performance for co-processed materials.  293 
3.2. Product characterization 294 
3.2.1. Microparticle composition. 295 
Table 1 also shows the composition of the co-processed powders. As it can be seen, the gOF/gpowder 296 
ratio of the products is in good agreement with the theoretical composition OF/(HA+OF). Since 297 
fluoroquinolones treatments require relative high doses, the high drug load (from 39 to 46 % of 298 
the product) in the microparticles is a valuable property of the formulated powders.  299 
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3.2.2. Fourier transformed Infrared spectroscopy 300 
The FT-IR spectra of the SD pure and co-processed materials were obtained and Table 4 shows the 301 
position of the characteristic peak wavelengths while in Figure 2 the FT-IR spectra can be seen. A 302 
broad band at around 1636 cm-1 corresponding to the carboxylic stretching was detected in the 303 
pure HA spectra. Other relevant bands for this compound were also found: one ascribed to the 304 
stretching of the amide I band (1650 cm-1) and the HC=C double bond stretching (1555 cm-1)43. The 305 
pure OF FT-IR spectra displayed the characteristic bands of ofloxacin: at 2784.17 cm-1 appeared 306 
the band ascribed to the stretching of the CH3-N and the band at 1408.5 cm
-1 was associated to 307 
the in-plane deformation of the CH3-N group. Besides, a peak ascribed to the C=O stretching of the 308 
carboxylic acid at 1717.15 cm-1 and another peak associated to the C=O ring carbonyl at 309 
1621.2 cm-1 can also be observed44. 310 
The spectra of the co-processed products showed some changes respect to the pure materials 311 
spectra. The two bands ascribed to the OF stretching and in-plane deformation of the CH3-N group 312 
completely disappeared. Simultaneously, two new bands appeared as shoulders at around 313 
1600 cm−1 and 1400 cm−1. They were ascribed to the C=O asymmetric and symmetric stretching of 314 
the carboxylate groups of HA, respectively. These bands were associated to the HA ionization due 315 
to the ionic interaction between the OF amine group and the HA carboxylic group.  316 
3.2.3.  X-ray diffraction 317 
Aiming to assess crystalline variations associated to the spray drying process and the interaction 318 
between components, X-ray diffractograms of OF (as received from the supplier), spray-dried pure 319 
OF and HA and the co-processed products were recorded (Figure 3). According to Figure 3a, pure 320 
OF displayed a crystalline structure. The position and relative intensity of the reflections were in 321 
good agreement with the ones reported by Peng et al.45. As it can be seen in Figure 3a, processing 322 
OF by spray drying did not affect its crystalline structure as the reflections were placed in the same 323 
angular positions that the ones of the raw OF. On the other hand, the spray-dried hyaluronic acid 324 
presented an amorphous structure; the baseline is elevated while no peaks can be observed 325 
(Figure 3a). 326 
Figure 3b shows that the co-processed materials, independently of the neutralization degree and 327 
the combination of SD process parameters used, were amorphous. In fact, the reflections 328 
corresponding to OF completely disappeared and the baseline is elevated between 15 and 30°, 329 
indicating complete crystallinity loss. This phenomenon is an indirect evidence of the interaction 330 
between the drug and the polyelectrolyte46. The X-ray diffractions of the co-processed materials 331 
(set I) demonstrated to be amorphous over five years storage, being then this structure stable for 332 
longer periods than shelf-life. The long-term stability of the amorphous state was previously 333 
demonstrated for others drug-polyelectrolyte inhalatory systems19.    334 
 335 
3.2.4. Particle morphology, drug and size distribution 336 
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Figures 4 and 5 show SEM micrographs of the drug (as received from the supplier), spray-dried 337 
pure OF and HA and the co-processed products. The pure drug without processing exhibited 338 
smooth and regular shaped crystals (Figure 4a), in good agreement with the OF morphology 339 
described by Duan et al.47 and with the OF crystalline structure demonstrated by X-ray diffraction. 340 
When the drug was processed by spray drying, crystal aggregates were observed (Figure 4b). The 341 
morphology of SD HA processed is shown in Figure 4c and corresponds to buckling smooth 342 
particles, in good agreement with results reported for other SD anionic polyelectrolytes18,48. 343 
Regarding the co-processed microparticles, Figures 5a to 5d show smooth rounded particles, with 344 
one or more concavities. The morphology was similar to the one observed for the pure SD HA. The 345 
apparent crystals lack is supported by the amorphous state detected by X-ray diffraction. As it can 346 
be seen, neither the process parameters nor the neutralization degree affected microparticles 347 
morphology. 348 
Aiming to study if all microparticles obtained by spray drying present OF, Figure 6 shows the laser 349 
scanning confocal micrographs. The fluorescence of sample (HA-OF)100 Set I was very high, 350 
saturating the image, for this reason is not presented. HA has not fluorescent properties while OF 351 
possesses a natural fluorophore given by the 4-keto oxygen and the ionized 3-carboxylic acid 352 
group49. Transmission image (Figure 6a) represents the whole polymeric microparticles, while in 353 
the fluorescent image (Figure 6b) only the OF is shown. As can be seen, all the particles present 354 
fluorescence, indicating the presence of the drug in all co-processed powder.  355 
Table 5 shows the mean volumetric diameter (D43), evaluated by laser diffraction for co-processed 356 
particles. The particles obtained by using set I showed D43 values of 7.31 and 6.90 µm for samples 357 
with neutralizations degrees of 75 and 100 %, respectively. On the other hand, the particles 358 
obtained using the parameters of set II exhibited D43 values of 3.74 and 3.40 µm for (HA-OF)75 and 359 
(HA-OF)100 materials, respectively. Differences between samples with different neutralization 360 
degree obtained by using the same set of operating conditions were not statistically significant (p-361 
value > 0.05). However, the set conditions significantly affected D43 values; statistically significant 362 
differences were found for samples with the same neutralization degree but processed under 363 
different operating conditions (set I and II, p-value < 0.05). These results indicate that increasing 364 
the atomization air flowrate and using a high-performance cyclone (set II) allowed reducing the D43 365 
value, a desired characteristic for inhalatory products. Besides, all materials showed narrow 366 
distributions (i.e., span values lower than 250). 367 
3.3.1. Aerodynamic behavior 368 
The aerosolization properties for the powders (HA-OF)75 and (HA-OF)100 obtained using the process 369 
parameters of sets I and II (see Table 2) were evaluated in an NGI cascade impactor. Table 6 shows 370 
the following aerosolization parameters: EF, FPF for different particle sizes (3, 5 and 6.4 µm), RF 371 
for particle sizes lower than 3 and 5 µm, MMAD and GSD. To obtain these parameters, a capsule 372 
filling of 25 mg was used in order to compare the results here presented with the ones reported by 373 
Hwang et al17., and Park et al.3 These authors used a capsule loading of 30 and 10 mg, respectively. 374 
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As can be seen, the aerosolization performance was not affected by the neutralization degree, no 375 
statistical differences were found for samples (HA-OF)75 and (HA-OF)100 (p-value > 0.05) for both 376 
set of conditions. However, statistically significant differences were found when the same sample 377 
was processed under the two different set of conditions (p-value < 0.05). Higher values of FPF and 378 
RF and lower MMADs were obtained for Set II. This can be related to the combination of a higher 379 
atomization air flow rate and a high-performance cyclone, combination that allows producing and 380 
collecting particles with smaller sizes. 381 
As can be seen in Table 6, EF was higher than 90 % in all cases, regardless the neutralization 382 
degree or the processing set of conditions. For the OF-chitosan formulation studied by Park et al.3, 383 
emitted fractions higher than 90 % and about 81 % with and without using lactose as a carrier 384 
were obtained. For the system OF-HA studied by Hwang et al.17, an EF of 94 % was found when a 385 
ratio of OF-HA powder:lactose 1:24 was used. The values obtained in this work are very high, 386 
considering that samples were not mixtured with carrier particles, and comparable with the EFs 387 
reported by Hwang et al. and Park et al. for mixtures of the co-processed materials and lactose3,17.  388 
For previously described inhalatory systems carrying OF, FPF for particles smaller than 6.4 µm was 389 
obtained by using a twin-impinger impactor. Values reported were 45 % and 43 % for the 390 
OF-chitosan and OF-HANa systems, respectively. For the formulations obtained in this work using 391 
set I operating conditions, this FPF was similar to the reported by those authors. However, higher 392 
values (~ 65 %) than those previously reported were obtained when set II operating conditions 393 
were used. Besides, nowadays the USP recommends the use of multi-stage cascade impactors22 394 
that allows calculating FPFs for different particle sizes (and stablishing, to some extent, in vitro – in 395 
vivo correlations20,51). For example, for treating pulmonary illnesses, particles should possess 396 
aerodynamic diameters lower than 5 µm52. As it can be seen in Table 6, FPF < 5 µm is around 58 % 397 
and RF < 5 µm is about 54 %. This result indicates that more than the 50 % of the powder loaded in 398 
the capsule can reach the lungs even when no carrier is used. 399 
Table 6 also shows the RFs for particles with aerodynamic diameters lower than 3 µm. Although 400 
particles with aerodynamic diameters lower 3 µm are associated to systemic administration of 401 
drugs by the inhalatory tract, in this work RF<3µm is used as an indicator of the microparticles 402 
fraction that can anatomically reach alveolar macrophages because these cells are located within 403 
the alveolus53. This fraction was around 37 % for particles obtained using set II, i.e. about 37 % of 404 
the OF dose can reach the deep lung and thus the alveolar macrophages. This fraction was around 405 
2 times higher than the one obtained for set I samples. 406 
The MMAD was around 3.8 and 2.7 µm for particles obtained by using set I and II, respectively 407 
(Table 6). In all cases, the GSD value indicated that the aerodynamic particle size distributions 408 
were narrow (GSD value lower than 354).  409 
As can be seen, sample (HA-OF)100 (set II) was the best in vitro formulation because it presents 410 
smaller aerodynamic diameters and better aerosolization performance than set I; and carries 411 




3.3.2. HA-OF dose preliminary estimation 414 
In this section, a dose to treat multi‐drug resistant‐TB was roughly estimated in order to test if 415 
(HA‐OF)100 (set II) powder could be administered in a conventional capsule‐based DPI. 416 
Quinsair™ maketed product delivers a 240 mg dose of nebulized levofloxacin and is approved for 417 
treating Pseudomonas aeruginosa infection in patients with cystic fibrosis. Reported MIC90 values 418 
for levofloxacin were 3255 and 6.2556 µg/mL against P. aeruginosa and M. tuberculosis, 419 
respectively. Regarding ofloxacin, 3217,55 µg/mL MIC90 value was found against P. aeruginosa and 420 
M. tuberculosis. As MIC90 values for treating P. aeruginosa infections are similar or higher than the 421 
ones needed for treating M. tuberculosis with ofloxacin and levofloxacin, it could be assumed that 422 
the Quinsair™ dose would be adequate to treat TB by the inhalatory administration.  423 
To calculate the dose for the co-processed materials, besides the analogy supposed in the previous 424 
paragraph, the following assumptions are considered: 425 
a) The levofloxacin solution (Quinsair™) for nebulization, that is administered by using a PARI 426 
e-flow rapid nebulizer, delivers a respirable delivered dose of 130 mg57.  427 
b) The presence of hyaluronic acid improves Ofloxacin microparticles pharmacodynamics and 428 
targeted indexes by a 50 %17.  429 
As Ofloxacin is the racemic mixture where only levofloxacin is the active ingredient, 260 mg of OF 430 
would be necessary to reach the same respirable dose delivered by Quinsair™. Considering that 431 
the presence of hyaluronic acid allows OF dose reduction by a half17, 130 mg of this drug would be 432 
required to be delivered.  433 
To administrate 130 mg of OF, 21 of a size 3 capsules filled with 25 mg of the formulation would 434 
be necessary, being this number unsuitable for therapy compliance. However, a size 3 capsule can 435 
be filled up to 100 mg of this co-processed material58. To evaluate the aerodynamic performance 436 
of the developed system from a highly loaded capsule, the inhalatory formulation was retested in 437 
the NGI equipment in the same conditions that the described in Section 2.2.6. Results are shown 438 
in Table 7. As can be seen, EF is almost 90 %. Although FPF and RF values decreased compared to 439 
the ones obtained when a 25 mg-loading capsule was used, results are still adequate for inhalatory 440 
administration of the formulation. In fact, most commercially available DPIs have a FPF for 441 
particles with aerodynamic diameters lower than 5 µm of 10-35 %25. The MMAD was lower than 3 442 
and the GSD value indicated that the aerodynamic particle size distribution was narrow54, as it was 443 
found in the assay with 25 mg of capsule loading. 444 
Considering a 100 mg capsule filling (which still presents good aerosolization properties) and a 445 
respirable fraction for particles with aerodynamic diameters lower than 5 µm of 42 % (Table 7), 7 446 
capsules would be enough to deliver 130 mg OF dose. Thus, the material has potentiality for the 447 
proposed application. In fact, there are commercial DPIs that require up to 10 capsules twice daily 448 
to deliver the dose.59 449 
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Finally, it should be taken into account that the new material reported in this work is in the early 450 
stages of development and further studies are needed to determine the required dose, the 451 
number of capsules and therapeutic scheme. 452 
3.4. Cell viability 453 
Employing the MTT colorimetric assay, the cytotoxic effect of the sample (HA-OF)100 (set II) on the 454 
CALU-3 cell line was evaluated. As can be seen in Figure 7, even at the highest concentration 455 
assayed, the cell viability differences between the control and the treatments were not statistically 456 
significant (p-value > 0.05).  457 
As mentioned in Section 3.3.2, the highest MIC90 dose for multi-drug resistant TB treatments 458 
reported is 32 µg/mL17. Considering 30 mL volume of pulmonary liquid available for drug 459 
dissolution2, 0.60 mM of ofloxacin (the highest concentration assayed in this work) is around 6.5 460 
times higher than the highest reported MIC90
17. Even though these results are auspicious, toxicity 461 
studies of high doses of ofloxacin and/or HA in the lung have not been addressed yet. Then, 462 
further studies are necessary to assess completely the safety of this new material. 463 
3.5. Mucoadhesion assay: Tensile Strength  464 
In order to increase the mucoadhesivity of formulations, hydrophilic polymers are usually 465 
incorporated. In general terms, these polymers possess good stickiness to mucosal membranes. 466 
There are several advantages of mucoadhesive like increasing dosage form residence time, 467 
reducing the frequency of the drug administration, improving drug targeting, among others29. 468 
Mucoadhesion is a phenomenon that has not been fully understood; several theories have been 469 
proposed but the process is probably the result of combined mechanisms. In this sense, 470 
Khutoryanskiy reports that mucoadhesion is a process with sequential steps: a) wetting and 471 
swelling, b) developing of physical bonds, c) interpenetrating and entangling, d) developing of 472 
chemical bonds29. 473 
Table 8 shows the maximum detachment force (MDF) and total work of adhesion (TWA) when OF, 474 
HA or the (HA-OF)100 (Set II) microparticles were attached to the mobile probe. The test was also 475 
carried out soaking the mobile probe without microparticles in the mucin solution. This can be 476 
considered as a control test in order to establish the minimum force required for the probe 477 
detachment. As expected, this assay showed the lowest MDF and TWA. As can be seen in Table 8, 478 
MDF and TWA values for pure OF and mucin were very close. Differences found between these 479 
two materials were not statistically different (p-value > 0.05), although they were higher for OF. 480 
On the other hand, the pure HA MDF and TWA values were higher and statistically significant 481 
compared to mucin and pure OF. What is more, the co-processed microparticles displayed the 482 
highest MDF and TWA values in the tensile test. Differences were statistically significant respect to 483 
the HA, OF and mucin (p-value < 0.05). This result suggests that the inclusion of the 484 
polyelectrolyte in the co‐processed material provides higher mucoadhesion to the respiratory 485 
mucosa compared to the free ofloxacin.
60
 Besides, the higher values for the (HA-OF)100 (Set II) 486 
compared to the pure HA could be related to the ionization of the carboxylic groups of HA. It has 487 
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been reported that carboxylic groups of anionic polymers form hydrogen-bonds with mucin, 488 
specifically with oligosaccharides. However, ionized anionic groups of polyelectrolytes repel mucin 489 
negatively charged surface and hydrogen bonds cannot be developed29. For co-processed 490 
materials, the neutralization of the HA anionic groups by OF would prevent repulsion allowing the 491 
formation of hydrogen bonds.   492 
According to the results of Li et al.
60
, higher mucoadhesiveness can be associated to longer lung 493 
residence time and lower systemic exposure. The mucoadhesive properties of the SD co-494 
processed product is particularly interesting in the pharmacotherapy with OF, as the residence 495 
time of the drug in the lung could be prolonged, decreasing the microparticle clearance61.  496 
4. Conclusions  497 
Based on the spray-drying technology, using a feed composed by an aqueous-based solution 498 
containing OF and HA (with high neutralization degrees), high atomization air flowrate and the use 499 
of a high-performance collection cyclone (set II), powders suitable for inhalatory administration 500 
were obtained with very good process yields.  501 
For formulations with neutralization degrees between 75-100 %, the powder OF loading was about 502 
50 % (w/w), being then the formulation appropriate to administrate high OF doses. The ionic 503 
interaction between OF and HA allowed stabilizing the amorphous nature of the co-processed 504 
products for over five years.  505 
The carrier-free formulation (HA-OF)100 set II showed excellent emitted, fine particle and respirable 506 
fractions. In fact, about the 50 % and 37 % of the OF loading in a 25 mg capsule would be able to 507 
reach the lungs (respirable fraction for aerodynamic particle size smaller than 5 µm) and the 508 
region where alveolar macrophages locate, respectively. The best formulation exhibited higher 509 
mucoadhesion than pure OF, property that can increase the drug residence time in the lungs. 510 
Comparing the amount of drug that would reach the lung with the required OF to treat TB, the 511 
estimated therapeutic dose could be provided by 7 capsules. Besides, the best formulation did not 512 
affect CALU-3 cell viability up to a dose 6.5 times higher than the MIC90 reported to treat multi-513 
drug resistant TB. Considering the auspicious in vitro results for the developed co-processed 514 
product, it is necessary to vigorous assess its stability, pharmacokinetics, and toxicity.  515 
 516 
5. Acknowledgements 517 
Financial support was received from UNS (PGI 24/B252), CONICET (PIP 11220150100704CO) and 518 
FONCyT (PICT-2016-0976). N. Ceschan and M. Rosas thank CONICET for their fellowships. The 519 
authors thank Rocío Rodriguez (UNS), Leandro Leidi (UNS), Federico Suldrup (UNS), Tatiana Odoux 520 
(PLAPIQUI) and Mariana LiCausi (Laboratorio Pablo Cassará) for their technical assistance and 521 




6. References 524 
1.  O’Donnell KP, Smyth HDC. Macro- and Microstructure of the Airways for Drug Delivery. In: 525 
Smyth HDC, Hickey AJ, eds. Controlled Pulmonary Drug Delivery. 1st Editio. Springer; 526 
2011:1-19. doi:10.1007/978-1-4419-9745-6 527 
2.  Olsson B, Bondesson E, Borgström L, et al. Pulmonary Drug Metabolism, Clearance, and 528 
Absorption. In: Smyth HDC, Hickey AJ, eds. Controlled Pulmonary Drug Delivery. 1st Edition. 529 
Springer; 2011:21-50. doi:10.1007/978-1-4419-9745-6 530 
3.  Park JH, Jin HE, Kim DD, Chung SJ, Shim WS, Shim CK. Chitosan microspheres as an alveolar 531 
macrophage delivery system of ofloxacin via pulmonary inhalation. Int J Pharm. 532 
2013;441:562-569. doi:10.1016/j.ijpharm.2012.10.044 533 
4.  Tsapis N, Bennett D, O’Driscoll K, et al. Direct lung delivery of para-aminosalicylic acid by 534 
aerosol particles. Tuberculosis. 2003;83(6):379-385. doi:10.1016/j.tube.2003.08.016 535 
5.  Hidalgo A, Cruz A, Pérez-Gil J. Barrier or carrier? Pulmonary surfactant and drug delivery. 536 
Eur J Pharm Biopharm. 2015;95:117-127. doi:10.1016/j.ejpb.2015.02.014 537 
6.  Gallo L, Bucalá V, Ramírez-Rigo MV. Formulation and characterization of polysaccharide 538 
microparticles for pulmonary delivery of sodium cromoglycate. AAPS PharmSciTech. 539 
2017;8(5):1634–1645. doi:10.4103/0973-8398.84552 540 
7.  Quinteros D, Ramirez Rigo MV, Jimenez Kairuz A, Olivera ME, Manzo RH, Allemandi D. 541 
Interaction between a cationic polymethacrylate (Eudragit E100) and anionic drugs. Eur J 542 
Pharm Sci. 2008;33(1):72-79. doi:10.1016/j.ejps.2007.10.002 543 
8.  Sikwal DR, Kalhapure RS, Rambharose S, et al. Polyelectrolyte complex of vancomycin as a 544 
nanoantibiotic: Preparation, in vitro and in silico studies. Mater Sci Eng C. 2016;63:489-498. 545 
doi:10.1016/j.msec.2016.03.019 546 
9.  Cheow WS, Hadinoto K. Green preparation of antibiotic nanoparticle complex as potential 547 
anti-biofilm therapeutics via self-assembly amphiphile-polyelectrolyte complexation with 548 
dextran sulfate. Colloids Surf B Biointerfaces. 2012;92:55-63. 549 
doi:10.1016/j.colsurfb.2011.11.024 550 
10.  Kho K, Hadinoto K. Dry powder inhaler delivery of amorphous drug nanoparticles: Effects of 551 
the lactose carrier particle shape and size. Powder Technol. 2013;233:303-311. 552 
doi:10.1016/j.powtec.2012.09.023 553 
11.  Zahoor A, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug 554 
carriers against experimental tuberculosis. Int J Antimicrob Agents. 2005;26(4):298-303. 555 
doi:10.1016/j.ijantimicag.2005.07.012 556 
12.  Swai H, Hillie KT, Cingo N, Kalombo L, Legodi M, Semete B. Evaluation of Nano 557 
Encapsulation Techniques in Different Polymeric System for the Delivery of Anti-558 
Tuberculosis Drugs (ATD). In: CSRI Conference 2016. Pretoria; 2006:1. 559 
13.  Manca ML, Valenti D, Sales OD, Nacher A, Fadda AM, Manconi M. Fabrication of 560 
polyelectrolyte multilayered vesicles as inhalable dry powder for lung administration of 561 
rifampicin. Int J Pharm. 2014;472:102-109. doi:10.1016/j.ijpharm.2014.06.009 562 
14.  Caminero JA, Cayla JA, García-garcía J, García-pérez FJ, Palacios JJ, Ruiz-manzano J. 563 
Diagnosis and Treatment of Drug-Resistant Tuberculosis. Arch Bronconeumol. 564 
2017;53(9):501-509. 565 
15.  Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines 566 
for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49:1-12. 567 
doi:10.1183/13993003.02308-2016 568 
16.  Rather MA, Amin S, Maqbool M, Bhat ZS, Gupta PN, Ahmad Z. Preparation and In Vitro 569 
Characterization of Albumin Nanoparticles Encapsulating an Anti-Tuberculosis Drug-570 
17 
 
Levofloxacin. Adv Sci Eng Med. 2016;8(11):912-917. doi:10.1166/asem.2016.1922 571 
17.  Hwang SM, Kim DD, Chung SJ, Shim CK. Delivery of ofloxacin to the lung and alveolar 572 
macrophages via hyaluronan microspheres for the treatment of tuberculosis. J Control 573 
Release. 2008;129(2):100-106. doi:10.1016/j.jconrel.2008.04.009 574 
18.  Ceschan NE, Bucalá V, Ramírez-Rigo MV. New alginic acid-atenolol microparticles for 575 
inhalatory drug targeting. Mater Sci Eng C Mater Biol Appl. 2014;41:255-266. 576 
doi:10.1016/j.msec.2014.04.040 577 
19.  Ceschan NE, Bucalá V, Ramírez-Rigo MV. Polymeric microparticles containing indomethacin 578 
for inhalatory administration. Powder Technol. 2015;285:51-61. 579 
doi:10.1016/j.powtec.2015.02.001 580 
20.  Copley-Scientific. Quality Solutions for Inhaler Testing. Brochure. 2019. 581 
21.  Ceschan NE, Bucalá V, Mateos MV, Smyth HDC, Ramírez-Rigo MV. Carrier free 582 
indomethacin microparticles for dry powder inhalation. Int J Pharm. 2018;549:169-178. 583 
doi:10.1016/j.ijpharm.2018.07.065 584 
22.  European Pharmacopoeia 7.0.; 2010. 585 
23.  Donovan MJ, Smyth HDC. Influence of size and surface roughness of large lactose carrier 586 
particles in dry powder inhaler formulations. Int J Pharm. 2010;402:1-9. 587 
doi:10.1016/j.ijpharm.2010.08.045 588 
24.  Du J, El-Sherbiny IM, Smyth HD. Swellable Ciprofloxacin-Loaded Nano-in-Micro Hydrogel 589 
Particles for Local Lung Drug Delivery. AAPS PharmSciTech. 2014;15(6):1535-1544. 590 
doi:10.1208/s12249-014-0176-x 591 
25.  Wang YB, Watts AB, Peters JI, Liu S, Batra A, Williams RO. In Vitro and In Vivo performance 592 
of dry powder inhalation formulations: comparison of particles prepared by thin film 593 
freezing and micronization. AAPS PharmSciTech. 2014;15(4):981-993. doi:10.1208/s12249-594 
014-0126-7 595 
26.  Valdivieso AG, Dugour A V., Sotomayor V, Clauzure M, Figueroa JM, Santa-Coloma TA. N-596 
acetyl cysteine reverts the proinflammatory state induced by cigarette smoke extract in 597 
lung Calu-3 cells. Redox Biol. 2018;16(March):294-302. doi:10.1016/j.redox.2018.03.006 598 
27.  Promega-Corporation. CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay.; 599 
2012. 600 
28.  Brown MB, Jones SA. Hyaluronic acid: A unique topical vehicle for the localized delivery of 601 
drugs to the skin. J Eur Acad Dermatology Venereol. 2005;19(3):308-318. 602 
doi:10.1111/j.1468-3083.2004.01180.x 603 
29.  Khutoryanskiy V. Advances in mucoadhesion and mucoadhesive polymers. Macromol 604 
Biosci. 2011;11(6):748-764. doi:10.1002/mabi.201000388 605 
30.  Martinelli F, Balducci AG, Kumar A, et al. Engineered sodium hyaluronate respirable dry 606 
powders for pulmonary drug delivery. Int J Pharm. 2016;517(1-2):286-295. 607 
doi:10.1016/j.ijpharm.2016.12.002 608 
31.  Rossi I, Buttini F, Sonvico F, et al. Sodium hyaluronate nanocomposite respirable 609 
microparticles to tackle antibiotic resistance with potential application in treatment of 610 
mycobacterial pulmonary infections. Pharmaceutics. 2019;11(5):1-23. 611 
doi:10.3390/pharmaceutics11050203 612 
32.  Gao Y, Sarfraz MK, Clas SD, Roa W, Löbenberg R. Hyaluronic acid-tocopherol succinate-613 
based self-assembling micelles for targeted delivery of rifampicin to alveolar macrophages. 614 
J Biomed Nanotechnol. 2014;11(8):1312-1329. doi:10.1166/jbn.2015.2091 615 
33.  Silva JP, Gonçalves C, Costa C, et al. Delivery of LLKKK18 loaded into self-assembling 616 




34.  Wu G, Chen L, Li H, Wang YJ. Hyaluronic acid as an internal phase additive to obtain 619 
ofloxacin/PLGA microsphere by double emulsion method. Biomed Mater Eng. 620 
2014;24(1):751-756. doi:10.3233/BME-130863 621 
35.  Battistini FD, Olivera ME, Manzo RH. Equilibrium and release properties of hyaluronic acid-622 
drug complexes. Eur J Pharm Sci. 2013;49(4):588-594. doi:10.1016/j.ejps.2013.04.023 623 
36.  Paul T, MacHesky ML, Strathmann TJ. Surface complexation of the zwitterionic 624 
fluoroquinolone antibiotic ofloxacin to nano-anatase TiO2 photocatalyst surfaces. Environ 625 
Sci Technol. 2012;46(21):11896-11904. doi:10.1021/es302097k 626 
37.  Ross L, Riley M. Solubilities of some variously quinolone antimicrobials substituted. Int J 627 
Pharm. 1990;63:237-250. doi:10.1016/0378-5173(90)90130-V 628 
38.  Romañuk CB, Manzo RH, Linck YG, Chattah AK, Monti GA, Olivera ME. Characterization of 629 
the Solubility and Solid-State Properties of Saccharin Salts of Fluoroquinolones. J Pharm Sci. 630 
2009;98(10):3788-3801. doi:10.1002/jps 631 
39.  Manzo RH, Jimenez-Kairuz AF, Olivera ME, Alovero F, Ramirez Rigo M V. Thermodynamic 632 
and Rheological Properties of Polyelectrolyte Systems. In: Polyelectrolytes, 633 
Thermodynamics and Rheology. Springer International Publishing Switzerland; 2014:215-634 
244. 635 
40.  Zordok WA, El-Shwiniy WH, El-Attar MS, Sadeek SA. Spectroscopic, thermal analyses, 636 
structural and antibacterial studies on the interaction of some metals with ofloxacin. J Mol 637 
Struct. 2013;1047:267-276. doi:10.1016/j.molstruc.2013.04.076 638 
41.  Schanté CE, Zuber G, Herlin C, Vandamme TF. Chemical modifications of hyaluronic acid for 639 
the synthesis of derivatives for a broad range of biomedical applications. Carbohydr Polym. 640 
2011;85:469-489. doi:10.1016/j.carbpol.2011.03.019 641 
42.  Tontul I, Topuz A. Spray-drying of fruit and vegetable juices: Effect of drying conditions on 642 
the product yield and physical properties. Trends Food Sci Technol. 2017;63:91-102. 643 
doi:10.1016/j.tifs.2017.03.009 644 
43.  Alkrad JA, Mrestani Y, Stroehl D, Wartewig S, Neubert R. Characterization of enzymatically 645 
digested hyaluronic acid using NMR, Raman, IR, and UV-Vis spectroscopies. J Pharm Biomed 646 
Anal. 2003;31(3):545-550. doi:10.1016/S0731-7085(02)00682-9 647 
44.  Sagdinc S, Bayari S. Spectroscopic studies on the interaction of ofloxacin with metals. J Mol 648 
Struct. 2004;691(1-3):107-113. doi:10.1016/j.molstruc.2003.11.053 649 
45.  Peng X, Zhang L, Kennedy JF. Release behavior of microspheres from cross-linked N-650 
methylated chitosan encapsulated ofloxacin. Carbohydr Polym. 2006;65(3):288-295. 651 
doi:10.1016/j.carbpol.2006.01.014 652 
46.  Ceschan NE, Bucalá V, Ramírez-Rigo MV. New alginic acid-atenolol microparticles for 653 
inhalatory drug targeting. Mater Sci Eng C. 2014;41. doi:10.1016/j.msec.2014.04.040 654 
47.  Duan J, Vogt FG, Li X, Hayes D, Mansour HM. Design, characterization, and aerosolization of 655 
organic solution advanced spray-dried moxifloxacin and ofloxacin 656 
dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for 657 
pulmonary inhalation aerosol delivery. Int J Nanomedicine. 2013;8:3489-3505. 658 
doi:10.2147/IJN.S48631 659 
48.  Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 660 
2008;25(5):999-1022. doi:10.1007/s11095-007-9475-1 661 
49.  Park HR, Oh CH, Lee HC, Choi JG, Jung BI, Bark KM. Quenching of ofloxacin and flumequine 662 
fluorescence by divalent transition metal cations. Bull Korean Chem Soc. 2006;27(12):2002-663 
2010. doi:10.5012/bkcs.2006.27.12.2002 664 
50.  Palazzo F, Giovagnoli S, Schoubben A, Blasi P, Rossi C, Ricci M. Development of a spray-665 
drying method for the formulation of respirable microparticles containing ofloxacin – 666 
19 
 
palladium complex. Int J Pharm. 2013;440(2):273-282. doi:10.1016/j.ijpharm.2012.05.045 667 
51.  Newman SP, Chan HK. In Vitro/In Vivo Comparisons in Pulmonary Drug Delivery. J Aerosol 668 
Med Pulm Drug Deliv. 2008;21(1):77-84. doi:10.1089/jamp.2007.0643 669 
52.  Traini D. Inhalation Drug Delivery. In: Colombo P, Traini D, Buttini F, eds. Inhalation Drug 670 
Delivery: Techniques and Products. 1st Editio. John Wiley & Sons, Ltd; 2013:1-14. 671 
doi:10.1002/9781118397145.ch1 672 
53.  Laskin DL, Weinberger B, Laskin JD. Functional heterogeneity in liver and lung 673 
macrophages. J Leukoc Biol. 2001;70(2):163-170. doi:10.1189/jlb.70.2.163 674 
54.  Razavi Rohani SS, Abnous K, Tafaghodi M. Preparation and characterization of spray-dried 675 
powders intended for pulmonary delivery of insulin with regard to the selection of 676 
excipients. Int J Pharm. 2014;465:464-478. doi:10.1016/j.ijpharm.2014.02.030 677 
55.  Gönüllü N, Aktaş Z, Şalcioǧlu M, Bal Ç, Anǧ Ö. Comparative in vitro activities of five 678 
quinolone antibiotics, including gemifloxacin, against clinical isolates. Clin Microbiol Infect. 679 
2001;7(9):499-503. doi:10.1046/j.1198-743X.2001.00297.x 680 
56.  Ogasawara K, Sato K, Tomioka H. Comparative in vitro antimicrobial activity of the newly 681 
synthesized quinolones WQ-3034 and HSR-903 and other quinolones against 682 
Mycobacterium tuberculosis and Mycobacterium avium complex. Japanese J Chemother. 683 
2000;48(12):892-897. doi:10.11250/chemotherapy1995.48.892 684 
57.  Loutit JS., Morgan EE., Dudley MN., Griffith DC., Lomovskaya O. US 10,231,975 B2. Use of 685 
aerolized levofloxacin for treating cystic fibrosis. 2014. 686 
58.  Weers JG, Miller DP, Tarara TE. Spray-Dried PulmoSphereTM Formulations for Inhalation 687 
Comprising Crystalline Drug Particles. AAPS PharmSciTech. 2019;20(3):1-15. 688 
doi:10.1208/s12249-018-1280-0 689 
59.  EMA EMA. Bronchitol (Mannitol).; 2012. doi:10.1163/187103210x528192 690 
60.  Li Y, Han M, Fang TLDCL, Yangac M. Inhaled hyaluronic acid microparticles extended 691 
pulmonary retention and suppressed systemic exposure of a short-acting bronchodilator. 692 
Carbohydr Polym. 2017;172:197-204. 693 
61.  Ungaro F, D’Angelo I, Miro A, La Rotonda MI, Quaglia F. Engineered PLGA nano- and micro-694 
carriers for pulmonary delivery: Challenges and promises. J Pharm Pharmacol. 695 
2012;64(9):1217-1235. doi:10.1111/j.2042-7158.2012.01486.x 696 
 697 
Table captions 
Table 1. Theoretical composition and experimental pH and composition of the feed solutions and 
powders 
Table 2. Process conditions for set I and II 
Table 3. Process yield (PY) and outlet air temperature (Tout) for different process parameters and 
formulations 
Table 4. Assignments of the FT-IR bands of HA, OF and the co-processed products obtained by 
spray drying  
Table 5. Mean volumetric diameter (D43) and span value for co-processed samples, as measured 
using laser diffraction 
Table 6. Aerosolization performance for co-processed samples using 25 mg-capsule loading 
Table 7. Aerosolization performance for co-processed samples using 100 mg-capsule loading 




Table 1. Theoretical composition and experimental pH and composition of the feed solutions and 
powders 
Sample  Theoretical values Experimental values 



















(HA-OF)75 0.28 0.21 49 0.43 4.03 0.40±0.01 0.39±0.01 
(HA-OF)100 0.28 0.28   56 0.50 5.08 0.46±0.02 0.46±0.02 
  
Table 2. Process conditions for set I and II 
Process conditions Set  
 I II 
Air inlet temperature (co-
current) (°C) 
110 110 
Feed solution flowrate (mL/min) 3.5 3.5 
Atomization air flowrate (L/h) 400 742 
Drying air flowrate (m
3
/h) 35 35 
Cyclone Standard High-performance 
 
  
Table 3. Process yield (PY) and outlet air temperature (Tout) for different process parameters and 
formulations 
 Set I Set II 
Sample  PY (%) Tout (°C) PY (%) Tout (°C) 
(HA-OF)75 53 70 69 58 
(HA-OF)100 51 71 74 52 
 
  
Table 4. Assignments of the FT-IR bands of HA, OF and the co-processed products obtained by 
spray drying  
Compound 
 Set I Set II 
Band (cm
-1
) OF HA (HA-OF)75 (HA-OF)100 (HA-OF)75 (HA-OF)100 
ν COOH  1717.2 1636.2 1732.9 1729.5 1724.6 1727.6 
ν C=O ring 1622.3 - 1622.1 1622.2 1621.1 1621.4 
ν CH3-N  2784.2 - - -   
δ CH3-N  1408.5 - - -   
ν amide I band  - 1650.7 1657.0 1658.4 1658.3 1659.6 
ν HC=C  - 1555.5 1544.5 1540.2 1544.2 1544.2 
ν COO- s asymmetric   - - 1608.8 1607.7 1607.6 1607.2 
ν COO- s symmetric - - 1416.5 1417.3 1414.7 1415.6 
s: the bands were seen as shoulders 
ν: stretching band 
δ: deformation band 
  
Table 5. Mean volumetric diameters (D43) and particle size distribution span values, as measured 
using laser diffraction 
 
 Set I  Set II  
NGI parameter (HA-OF)75 (HA-OF)100 (HA-OF)75 (HA-OF)100 
D43 7.31±0.46 6.90±0.63 3.10±0.23 3.39±0.31 
Span 0.92±0.17 0.92±0.14 1.13±0.17 0.99±0.21 
 
  
Table 6. Aerosolization performance using 25 mg-capsule loading 
 Set I  Set II  
NGI parameter (HA-OF)75 (HA-OF)100 (HA-OF)75 (HA-OF)100 
EF (%) 94.84±0.87 90.82±2.76 93.65±1.40 92.35±2.30 
FPF < 6.4µm (%) 49.21±2.09 44.28±1.76 60.14±4.90 67.84±3.20 
FPF < 5µm (%) 29.12±1.10 32.68±1.43 56.82±4.27 57.90±0.33 
FPF < 3µm (%) 15.87±2.99 20.50±3.32 39.67±2.78 40.89±1.10 
RF < 5µm (%) 27.63±1.25 28.90±2.09 52.90±3.41 53.45±1.03 
RF < 3µm (%) 15.06±2.85 18.17±3.19 36.95±2.72 38.70±2.26 
MMAD (µm) 3.89±0.83 3.68±0.23 2.80±0.28 2.70±0.17 
GSD 2.14±0.50 1.96±0.17 1.86±0.09 2.29±0.04 
EF: Emitted Fraction; FPF: Fine Particle Fraction; RF: Respirable Fraction; MMAD: Mass Median Aerodynamic 
Diameter; GSD: Geometric Standard Deviation 
Table 7. Aerosolization performance for co-processed samples using 100 mg-capsule loading 
NGI parameter (HA-OF)100 Set II 
EF % 89.18±1.28 
FPF < 5µm (%) 48.82±2.06 
FPF < 3µm (%) 33.85±2.97 
RF < 5µm (%) 42.50±3.09 
RF < 3µm (%) 29.63±3.21 
MMAD (µm) 2.95±0.33 
GSD 2.15±0.44 
EF: Emitted Fraction; FPF: Fine Particle Fraction; RF: Respirable Fraction; MMAD: Mass Median Aerodynamic 
Diameter; GSD: Geometric Standard Deviation 
  
 
Table 8. Maximum detachment force (MDF) and total work of adhesion (TWA) in the tensile test 
for powders. 
 
Material MDF (N) TWA (J, x10-4) 
Mucin 0.51±0.04 6.25±1.49 
OF: Mucin 0.58±0.05 7.30±1.09 
HA: Mucin 0.97±0.12 11.16±1.79 
(HA-OF)100 (Set II): Mucin 1.36±0.08 17.91±2.80 
 







